DYAI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Apr 2024 @ 16:00):

Stats
Today's Volume	8 238.00
Average Volume	23 388.00
Market Cap	44.33M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.37
ATR14	$0.0140 (0.90%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Lucy Patrick K.	Buy	13 125	Stock Option
2024-04-11	Tarnok Michael P.	Sell	13 125	Stock Option
2024-04-11	Hazelton Joseph P	Buy	20 000	Stock Option
2024-03-13	Hazelton Joseph P	Buy	41 720	Common Stock
2024-03-13	Emalfarb Mark A	Buy	124 454	Common Stock

INSIDER POWER
81.71
Last 99 transactions
Buy: 3 507 936 \| Sell: 1 014 811

Dyadic International Inc Correlation

10 Most Positive Correlations
RMRM	0.973
TLGT	0.916
APOP	0.914
FCNCA	0.9
SVAC	0.897
TDAC	0.895
XERS	0.885
AQST	0.885
BRKS	0.885
BLRX	0.884

10 Most Negative Correlations
MMAC	-0.936
NETE	-0.919
AMRB	-0.908
AEY	-0.897
BOCH	-0.893
TRUP	-0.89
PBHC	-0.887
EM	-0.884
MTP	-0.882
OBT	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dyadic International Inc Financials

Annual	2023
Revenue:	$2.90M
Gross Profit:	$922 957 (31.84 %)
EPS:	$-0.240

Q4	2023
Revenue:	$686 535
Gross Profit:	$336 417 (49.00 %)
EPS:	$-0.0719

Q3	2023
Revenue:	$397 060
Gross Profit:	$291 191 (73.34 %)
EPS:	$-0.0560

Q2	2023
Revenue:	$837 159
Gross Profit:	$44 215.00 (5.28 %)
EPS:	$-0.0747

Financial Reports:

No articles found.

Dyadic International Inc

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.